Applied Clinical Trials Magazine’s Post

View organization page for Applied Clinical Trials Magazine

15,379 followers

18h

#Tremfya could become the first IL-23 inhibitor with fully subcutaneous induction and maintenance options in the treatment of moderately to severely active #ulcerativecolitis.

ASTRO Trial Shows SC Tremfya Provides Significant Clinical Benefits in Moderately to Severely Active Ulcerative Colitis

appliedclinicaltrialsonline.com

To view or add a comment, sign in

15,379 followers

View Profile Follow

Explore topics

Sales
Marketing
IT Services
Business Administration
HR Management
Engineering
Soft Skills
See All

Applied Clinical Trials Magazine’s Post

ASTRO Trial Shows SC Tremfya Provides Significant Clinical Benefits in Moderately to Severely Active Ulcerative Colitis

appliedclinicaltrialsonline.com

More from this author

February's Featured Virtual Events

February's Featured Virtual Events

January's Featured Virtual Events

Explore topics